INTELLION Trademark
Trademark Overview
On Thursday, December 9, 2021, a trademark application was filed for INTELLION with the United States Patent and Trademark Office. The USPTO has given the INTELLION trademark a serial number of 97164075. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 18, 2024. This trademark is owned by C2i Genomics, Inc.. The INTELLION trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:
Genetic testing for medical purposes; medical diagnostic testing, monitoring and reporting services; medical testing and diagnostic services, namely, diagnostic testing, monitoring, tracking, and reporting for detecting minimal residual disease (MRD) by analyzing, testing, tracking, and reporting DNA, genomes, genotype, and genetic mutations using whole genome pattern recognition, low-input liquid blood biopsy, aggregated SNC and CNV signals, and tracking tumor progression as it evolves during the patient treatment and follow up period
Software-as-a-Service (SaaS) services featuring non-downloadable computer software and Platform-as-a-Service (PaaS) non-downloadable computer software services featuring computer software platforms in the nature of non-downloadable computer software, non-downloadable computer applications, and web-based software, all for accessing cloud-based servers and remote client servers for measuring pre and post-surgical cancer, medical, and disease burden scores through bioinformatics and artificial intelligence, analyzing, testing, tracking, and reporting genetic patterns post-pre- and surgery, providing cancer, medical, and disease treatment recommendation, providing high precision personalized cancer, medical, and disease treatment monitoring throughout the patient cancer, medical, and disease encounter, reducing cancer, medical, and disease treatment costs, and accelerated cancer, medical, and disease drug development for use by pharmaceutical companies and laboratories, health systems, onc...
General Information
| Serial Number | 97164075 |
| Word Mark | INTELLION |
| Filing Date | Thursday, December 9, 2021 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, November 18, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 25, 2022 |
Trademark Statements
| Goods and Services | Genetic testing for medical purposes; medical diagnostic testing, monitoring and reporting services; medical testing and diagnostic services, namely, diagnostic testing, monitoring, tracking, and reporting for detecting minimal residual disease (MRD) by analyzing, testing, tracking, and reporting DNA, genomes, genotype, and genetic mutations using whole genome pattern recognition, low-input liquid blood biopsy, aggregated SNC and CNV signals, and tracking tumor progression as it evolves during the patient treatment and follow up period |
| Goods and Services | Software-as-a-Service (SaaS) services featuring non-downloadable computer software and Platform-as-a-Service (PaaS) non-downloadable computer software services featuring computer software platforms in the nature of non-downloadable computer software, non-downloadable computer applications, and web-based software, all for accessing cloud-based servers and remote client servers for measuring pre and post-surgical cancer, medical, and disease burden scores through bioinformatics and artificial intelligence, analyzing, testing, tracking, and reporting genetic patterns post-pre- and surgery, providing cancer, medical, and disease treatment recommendation, providing high precision personalized cancer, medical, and disease treatment monitoring throughout the patient cancer, medical, and disease encounter, reducing cancer, medical, and disease treatment costs, and accelerated cancer, medical, and disease drug development for use by pharmaceutical companies and laboratories, health systems, oncologists, physicians, cancer clinics, medical professionals, hospitals, and patients |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, December 14, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, December 14, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | VERACYTE DIAGNOSTICS, LLC |
| Party Type | 21 - New Owner After Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | New York, NY 10014 |
| Party Name | C2i Genomics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10014 |
| Party Name | C2i Genomics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10014 |
Trademark Events
| Event Date | Event Description |
| Monday, December 13, 2021 | NEW APPLICATION ENTERED |
| Tuesday, December 14, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, September 17, 2022 | ASSIGNED TO EXAMINER |
| Saturday, September 17, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, October 5, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 25, 2022 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 25, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Monday, November 21, 2022 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Sunday, March 5, 2023 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Tuesday, April 18, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, October 9, 2023 | SOU TEAS EXTENSION RECEIVED |
| Monday, October 9, 2023 | SOU EXTENSION 1 FILED |
| Monday, October 9, 2023 | SOU EXTENSION 1 GRANTED |
| Wednesday, October 11, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, March 7, 2024 | SOU TEAS EXTENSION RECEIVED |
| Thursday, March 7, 2024 | SOU EXTENSION 2 GRANTED |
| Thursday, March 7, 2024 | SOU EXTENSION 2 FILED |
| Friday, March 8, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, July 11, 2024 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Tuesday, August 6, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, August 6, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, August 6, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, August 6, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, August 6, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, November 18, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| Monday, November 18, 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
